Tyler J Varisco, Hannah Fish, Joshua Bolin, David Dadiomov, Lucas G Hill, Ekere J Essien, Matthew A Wanat, Diane Ginsburg, Jeanne Waggener, Sahar Yazdanfard, Juhyeon Song, Whanhui Chi, Douglas Thornton
BACKGROUND: Less than half of community pharmacies in the United States stock buprenorphine products indicated for the treatment of opioid use disorder. This lack of access to buprenorphine in community pharmacies is a significant barrier to care. To address this issue, this protocol outlines a comprehensive approach to develop a practice guideline aimed at improving access to safe and effective opioid use disorder treatment in community pharmacies. METHODS: The guideline development process will proceed in three phases, following a technique closely aligned with the Institute of Medicine's guidance on guideline development...
April 25, 2024: Archives of Public Health, Archives Belges de Santé Publique